SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (5619)9/15/1998 11:22:00 PM
From: poodle   of 9719
 
Mike, I would be careful with AAV. Idea was very good because of AAV specific integration site, but vector has low capacity. If my memory is correct, some article described system of 3 different AAV constructs used simultaniously to overcome this problem. Unfortunately, that's not the only problem. This spring I talked to gene therapy experts about different vectors, mainly adenoviruses, AAV and retroviruses. I have been told that AAV demonstrated low efficiency in vivo. More than, expression of the inserted constructs in vivo declined sharply. Retroviruses looked better for them, but very far from medical appl. either. I had been told also that there are many psychological problems yet.
Gene therapy, in it's "classical" or broader meaning, will be the most serious advantage of medicine, if not the only real medicine at all, but effective methods for DNA transfer should be developed first.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News